ACE-inhibitors (or angiotensin-receptor blockers in case of ACE-i intolerance) are recommended in patients with chronic coronary syndrome and coexisting hypertension, left ventricular dysfunction (LVEF ≤ 40%), chronic kidney disease or diabetes, while their benefit tend to disappear in the absence of heart failure or high cardiovascular risk [4,49,50,51]. This evidence concerns the gene ACE and heart failure.